TRINTELLIX SIDE EFFECTS
- Generic Name: vortioxetine tablets
- Brand Name: Trintellix
- Drug Class: Antidepressants, Other
SIDE EFFECTS
The following adverse reactions are discussed in greater detail in other sections of the label.
- Hypersensitivity
- Clinical Worsening and Suicide Risk
- Serotonin Syndrome
- Abnormal Bleeding
- Activation of Mania/Hypomania
- Discontinuation Syndrome
- Angle Closure Glaucoma
- Hyponatremia
Clinical Studies Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in clinical practice.
Patient Exposure
TRINTELLIX was evaluated for safety in 5852 patients (18 years to 88 years of age) diagnosed with MDD who participated in pre-and postmarketing clinical studies; 2616 of those patients were exposed to TRINTELLIX in 6 to 8 week, placebo-controlled studies at doses ranging from 5 mg to 20 mg once daily; 204 patients were exposed to TRINTELLIX in a 24 to 64 week placebo-controlled maintenance study at doses of 5 mg to 10 mg once daily; and 429 patients were exposed to TRINTELLIX in a 32 week placebo-controlled maintenance study in the U.S. at doses of 5 mg, 10 mg, and 20 mg, once daily. Patients from the 6 to 8 week studies continued into 12-month open-label studies. A total of 2586 patients were exposed to at least one dose of TRINTELLIX in open-label studies, 1727 were exposed to TRINTELLIX for 6 months and 885 were exposed for at least 1 year.
Adverse Reactions Reported As Reasons For Discontinuation Of Treatment
In pooled 6 to 8 week placebo-controlled studies the incidence of patients who received TRINTELLIX 5 mg/day, 10 mg/day, 15 mg/day and 20 mg/day and discontinued treatment because of an adverse reaction was 5%, 6%, 8% and 8%, respectively, compared to 4% of placebo-treated patients. Nausea was the most common adverse reaction reported as a reason for discontinuation.
Common Adverse Reactions In Placebo-Controlled MDD Studies
The most commonly observed adverse reactions in MDD patients treated with TRINTELLIX in 6 to 8 week placebo-controlled studies (incidence ≥5% and at least twice the rate of placebo) were nausea, constipation and vomiting.
Table 1 shows the incidence of common adverse reactions that occurred in ≥2% of MDD patients treated with any TRINTELLIX dose and at least 2% more frequently than in placebo-treated patients in the 6 to 8 week placebo-controlled studies.
Table 1. Common Adverse Reactions Occurring in ≥2% of Patients Treated with AnyTRINTELLIX Dose and at Least 2% Greater Than the Incidence in Placebo-Treated Patients
| System Organ Class Preferred Term | TRINTELLIX 5 mg/day |
TRINTELLIX 10 mg/day |
TRINTELLIX 15 mg/day |
TRINTELLIX 20 mg/day |
Placebo |
| N=1013 % |
N=699 % |
N=449 % |
N=455 % |
N=1621 % |
|
| Gastrointestinal disorders | |||||
| Nausea | 21 | 26 | 32 | 32 | 9 |
| Diarrhea | 7 | 7 | 10 | 7 | 6 |
| Dry mouth | 7 | 7 | 6 | 8 | 6 |
| Constipation | 3 | 5 | 6 | 6 | 3 |
| Vomiting | 3 | 5 | 6 | 6 | 1 |
| Flatulence | 1 | 3 | 2 | 1 | 1 |
| Nervous system disorders | |||||
| Dizziness | 6 | 6 | 8 | 9 | 6 |
| Psychiatric disorders | |||||
| Abnormal dreams | <1 | <1 | 2 | 3 | 1 |
| Skin and subcutaneous tissue disorders | |||||
| Pruritus* | 1 | 2 | 3 | 3 | 1 |
| * includes pruritus generalized | |||||
Nausea
Nausea was the most common adverse reaction and its frequency was dose-related (Table 2). It was usually considered mild or moderate in intensity and the median duration was two weeks. Nausea was more common in females than males. Nausea most commonly occurred in the first week of TRINTELLIX treatment with 15 to 20% of patients experiencing nausea after one to two days of treatment. Approximately 10% of patients taking TRINTELLIX 10 mg/day to 20 mg/day had nausea at the end of the 6 to 8 week placebo-controlled studies.
Sexual Dysfunction
Difficulties in sexual desire, sexual performance and sexual satisfaction often occur as manifestations of psychiatric disorders, but they may also be consequences of pharmacologic treatment. In addition to the data from the MDD studies mentioned below, TRINTELLIX has been prospectively assessed for its effects in MDD patients with existing TESD induced by prior SSRI treatment and in healthy adults with normal sexual function at baseline.
Voluntarily Reported Adverse Reactions Of Sexual Dysfunction
In the MDD 6 to 8 week controlled trials of TRINTELLIX, voluntarily reported adverse reactions related to sexual dysfunction were captured as individual event terms. These event terms have been aggregated and the overall incidence was as follows. In male patients the overall incidence was 3%, 4%, 4%, 5% in TRINTELLIX 5 mg/day, 10 mg/day, 15 mg/day, 20 mg/day, respectively, compared to 2% in placebo. In female patients, the overall incidence was <1%, 1%, <1%, 2% in TRINTELLIX 5 mg/day, 10 mg/day, 15 mg/day, 20 mg/day, respectively, compared to <1% in placebo.
Adverse Reactions Of Sexual Dysfunction In Patients With Normal Sexual Functioning At Baseline
Because voluntarily reported adverse sexual reactions are known to be underreported, in part because patients and physicians may be reluctant to discuss them, the Arizona Sexual Experiences Scale (ASEX), a validated measure designed to identify sexual side effects, was used prospectively in seven placebo-controlled trials. The ASEX scale includes five questions that pertain to the following aspects of sexual function: 1) sex drive, 2) ease of arousal, 3) ability to achieve erection (men) or lubrication (women), 4) ease of reaching orgasm, and 5) orgasm satisfaction.
The presence or absence of sexual dysfunction among patients entering clinical studies was based on their self-reported ASEX scores. For patients without sexual dysfunction at baseline (approximately 1/3 of the population across all treatment groups in each study), Table 3 shows the incidence of patients that developed TESD when treated with TRINTELLIX or placebo in any fixed dose group. Physicians should routinely inquire about possible sexual side effects.
Table 2. ASEX Incidence of Treatment Emergent Sexual Dysfunction*
| TRINTELLIX 5mg/day N=65:67† |
TRINTELLIX 10mg/day N=94:86† |
TRINTELLIX 15mg/day N=57:67† |
TRINTELLIX 20mg/day N=67:59† |
Placebo N=135:162† | |
| Females | 22% | 23% | 33% | 34% | 20% |
| Males | 16% | 20% | 19% | 29% | 14% |
| * Incidence based on number of subjects with sexual dysfunction during the study/number of subjects without sexual dysfunction at baseline. Sexual dysfunction was defined as a subject scoring any of the following on the ASEX scale at two consecutive visits during the study: 1) total score ≥19; 2) any single item ≥5; 3) three or more items each with a score ≥4 † Sample size for each dose group is the number of patients (females:males) without sexual dysfunction at baseline |
|||||
Adverse Reactions Following Abrupt Discontinuation Of TRINTELLIX Treatment
Discontinuation symptoms have been prospectively evaluated in patients taking TRINTELLIX 10 mg/day, 15 mg/day, and 20 mg/day using the Discontinuation-Emergent Signs and Symptoms (DESS) scale in clinical trials. Some patients experienced discontinuation symptoms such as headache, muscle tension, mood swings, sudden outbursts of anger, dizziness, and runny nose in the first week of abrupt discontinuation of TRINTELLIX 15 mg/day and 20 mg/day.
Laboratory Tests
TRINTELLIX has not been associated with any clinically important changes in laboratory test parameters in serum chemistry (except sodium), hematology and urinalysis as measured in the 6 to 8 week placebo-controlled studies. Hyponatremia has been reported with the treatment of TRINTELLIX. In the 6-month, double-blind, placebo-controlled phase of a long-term study in patients who had responded to TRINTELLIX during the initial 12 week, open-label phase, there were no clinically important changes in lab test parameters between TRINTELLIX and placebo-treated patients.
Weight
TRINTELLIX had no significant effect on body weight as measured by the mean change from baseline in the 6 to 8 week placebo-controlled studies. In the six month, double-blind, placebo-controlled phase of a long-term study in patients who had responded to TRINTELLIX during the initial 12-week, open-label phase, there was no significant effect on body weight between TRINTELLIX and placebo-treated patients.
Vital Signs
TRINTELLIX has not been associated with any clinically significant effects on vital signs, including systolic and diastolic blood pressure and heart rate, as measured in placebo-controlled studies.
Other Adverse Reactions Observed In Clinical Studies
The following listing does not include reactions: 1) already listed in previous tables or elsewhere in labeling, 2) for which a drug cause was remote, 3) which were so general as to be uninformative, 4) which were not considered to have significant clinical implications, or 5) which occurred at a rate equal to or less than placebo.
Ear and labyrinth disorders – vertigo
Gastrointestinal disorders – dyspepsia
Nervous system disorders – dysgeusia
Vascular disorders – flushing
Postmarketing Experience
The following adverse reactions have been identified during postapproval use of TRINTELLIX. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Endocrine disorders – hyperprolactinemia
Gastrointestinal System – acute pancreatitis
Immune system disorders – hypersensitivity reactions (including anaphylaxis and urticaria)
Metabolic disorders– weight gain
Nervous system disorders – seizure, headache
Psychiatric disorders – aggression, agitation, anger, hostility, irritability
Skin and subcutaneous tissue disorders – rash, generalized rash, hyperhidrosis
SRC: NLM .